1-3 of 3
Esther Lilienweiss
Close
Sort by
Journal Articles

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

Clinical Trials & Observations
Othman Al-Sawaf, Esther Lilienweiss, Jasmin Bahlo, Sandra Robrecht, Anna-Maria Fink, Michaela Patz, Maneesh Tandon, Yanwen Jiang, William Schary, Matthias Ritgen, Eugen Tausch, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Karl-Anton Kreuzer
Journal: Blood
Blood (2020) 135 (11): 866–870.
https://doi.org/10.1182/blood.2019003451
Published: 2020
Includes: Supplemental data
Journal Articles

ROR-1 Is a Highly Discriminative Marker in Flow Cytometric Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL)

Michaela Patz, Barbara Pentok, Kathrin Cremer, Stefanie Linnartz, Esther Lilienweiss, Fanni Kleinert, Michael Hallek, MD, Karl-Anton Kreuzer
Journal: Blood
Blood (2016) 128 (22): 3197.
https://doi.org/10.1182/blood.V128.22.3197.3197
Published: 2016
Journal Articles

Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia

Karl-Anton Kreuzer, Richard R. Furman, Stephan Stilgenbauer, Ronald L. Dubowy, Yeonhee Kim, Veerendra Munugalavadla, Esther Lilienweiss, Hans Christian Reinhardt, Andrew R. Pettitt, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 192.
https://doi.org/10.1182/blood.V128.22.192.192
Published: 2016